CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $578 | -99.9% | 10,764 | -1.2% | 0.05% | -31.9% |
| Q1 2024 | $742,740 | +7.7% | 10,897 | -1.0% | 0.07% | +30.2% |
| Q4 2023 | $689,351 | +30.9% | 11,012 | -5.1% | 0.05% | -41.8% |
| Q3 2023 | $526,569 | +87369.9% | 11,601 | +8.1% | 0.09% | +71.7% |
| Q2 2023 | $602 | +20.9% | 10,731 | -2.6% | 0.05% | +29.3% |
| Q1 2023 | $498 | -100.0% | 11,014 | +94.6% | 0.04% | +105.0% |
| Q4 2022 | $230,119,650 | +44933.2% | 5,661 | -27.6% | 0.02% | -60.0% |
| Q3 2022 | $511,000 | +26.2% | 7,821 | +17.3% | 0.05% | +22.0% |
| Q2 2022 | $405,000 | +46.2% | 6,668 | +166.1% | 0.04% | +32.3% |
| Q3 2021 | $277,000 | -8.6% | 2,506 | +2.2% | 0.03% | -27.9% |
| Q2 2021 | $303,000 | +21.2% | 2,452 | +53.4% | 0.04% | +22.9% |
| Q4 2020 | $250,000 | – | 1,598 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |